Kymera’s KT-621 Phase 1b Data for Atopic Dermatitis to Debut at AAD 2026 — Kymera Therapeutics, Inc.

Event summary

Kymera Therapeutics will present Phase 1b data for KT-621 in atopic dermatitis during a late-breaking oral session at the AAD 2026 Annual Meeting on March 28, 2026.
KT-621 is an investigational, once-daily oral degrader targeting STAT6, a key driver of Type 2 inflammation.
The drug is also in parallel Phase 2b trials for atopic dermatitis (BROADEN2) and asthma (BREADTH).
Type 2 inflammatory diseases affect over 140 million people globally.

The big picture

Kymera’s presentation at AAD 2026 underscores the growing interest in targeted protein degradation as a novel approach for treating immuno-inflammatory diseases. The focus on oral therapies aligns with broader industry trends toward patient-friendly treatments, particularly for chronic conditions like atopic dermatitis and asthma. Success in these trials could validate Kymera’s pipeline strategy and attract further investment in its degrader platform.

What we're watching

Clinical Efficacy: How the Phase 1b data will position KT-621 against existing treatments for atopic dermatitis.
Regulatory Pathway: The pace at which Kymera can advance KT-621 through Phase 2b trials and potential regulatory approvals.
Market Differentiation: Whether KT-621’s oral administration and targeted degradation mechanism will provide a competitive edge in the Type 2 inflammation space.